

Wockhardt Foundation and Biogetica collaborate to combat COVID 19

07 August 2020 | News

The research to develop the remedy is being conducted under Corival Life Sciences.



Mumbai based Biogetica and Wockhardt Foundation have come together to conduct multidisciplinary research into remedies and strategies to effectively combat the Novel Corona Virus.

The research to develop the remedy is being conducted under Corival Life Sciences in Mumbai, which boasts of one of its kind partnerships between global leaders in the field of Natural & Pharmaceutical Medicines.

Corival Life Sciences has conducted reviews of published 'in vivo', 'in vitro', and 'in silica' research on COVID 19 basis which their first product called 'Immunofree' was launched. Immunofree is now being entered into a pharma control trial along with reginmune, a product made by Biogetica that has already shown ground-breaking results in herpes trials.

The USP of the Corival Life Sciences protocol apart from all others is the fact that it combines evidence-based nutraceuticals and potent full-spectrum herbal extracts, into easy to use pills that synergistically work in multifaceted ways, during these unprecedented times. This protocol combines learnings from Allopathy, Ayurveda, TCM, and Vibrational therapies. Immunofree blends a wide variety of phytochemicals, such as alkaloids, polyphenols, flavonoids, saponins, terpenoids, lignans, Xantones, etc. These herbs have specifically been chosen based on research done in 2020.

'Immunofree' serves as a multifaceted solution to the issues prevalent today. This is a one of kind partnership between pharmaceutical and herbal medicine providers and it has yielded a specific multifaceted formula for this unprecedented time.